China’s first personalized neoantigen-targeted cancer vaccine receives NMPA’s clinical trial approval
- According the latest data released at the Clinical Trials Implied Approval section on the website of China's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), Likang Life Sciences (hereinafter referred to as "Likang") has received...

